Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBT (2016 - 2025)

Amphastar Pharmaceuticals has reported EBT over the past 13 years, most recently at $37.2 million for Q4 2025.

  • Quarterly results put EBT at $37.2 million for Q4 2025, down 24.57% from a year ago — trailing twelve months through Dec 2025 was $129.0 million (down 33.93% YoY), and the annual figure for FY2025 was $129.0 million, down 33.93%.
  • EBT for Q4 2025 was $37.2 million at Amphastar Pharmaceuticals, up from $21.5 million in the prior quarter.
  • Over the last five years, EBT for AMPH hit a ceiling of $63.6 million in Q3 2023 and a floor of -$140.6 million in Q4 2023.
  • Median EBT over the past 5 years was $31.8 million (2023), compared with a mean of $19.3 million.
  • Biggest five-year swings in EBT: skyrocketed 1045.28% in 2021 and later tumbled 416.41% in 2022.
  • Amphastar Pharmaceuticals' EBT stood at $27.2 million in 2021, then tumbled by 416.41% to -$85.9 million in 2022, then plummeted by 63.57% to -$140.6 million in 2023, then soared by 135.12% to $49.4 million in 2024, then fell by 24.57% to $37.2 million in 2025.
  • The last three reported values for EBT were $37.2 million (Q4 2025), $21.5 million (Q3 2025), and $39.3 million (Q2 2025) per Business Quant data.